-DOCSTART- -X- O
Objective. -X- _ O
The -X- _ O
purpose -X- _ O
of -X- _ O
this -X- _ O
investigation -X- _ O
was -X- _ O
to -X- _ O
study -X- _ O
the -X- _ O
effect -X- _ O
of -X- _ O
a -X- _ O
potent -X- _ B-Intervention
topical -X- _ I-Intervention
steroid -X- _ I-Intervention
, -X- _ I-Intervention
fluticasone -X- _ I-Intervention
propionate -X- _ I-Intervention
, -X- _ O
on -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
early -X- _ I-Patient
signs -X- _ I-Patient
and -X- _ I-Patient
symptoms -X- _ I-Patient
of -X- _ I-Patient
the -X- _ I-Patient
common -X- _ I-Patient
cold. -X- _ I-Patient
To -X- _ O
characterize -X- _ O
the -X- _ O
mucosal -X- _ O
inflammatory -X- _ O
response -X- _ O
, -X- _ O
salivary -X- _ O
defense -X- _ O
factors -X- _ O
and -X- _ O
flow -X- _ O
rate -X- _ O
in -X- _ O
these -X- _ O
patients -X- _ O
were -X- _ O
analyzed. -X- _ O
Study -X- _ O
Design. -X- _ O
Forty -X- _ B-Patient
patients -X- _ I-Patient
with -X- _ O
symptoms -X- _ O
of -X- _ O
the -X- _ O
common -X- _ O
cold -X- _ O
were -X- _ O
randomized -X- _ O
into -X- _ O
2 -X- _ O
groups -X- _ O
to -X- _ O
receive -X- _ O
either -X- _ O
high-dose -X- _ B-Intervention
fluticasone -X- _ I-Intervention
propionate -X- _ I-Intervention
( -X- _ I-Intervention
100 -X- _ I-Intervention
μg -X- _ I-Intervention
per -X- _ I-Intervention
nostril -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ O
placebo -X- _ B-Comparison
4 -X- _ I-Comparison
times -X- _ I-Comparison
daily -X- _ I-Comparison
for -X- _ I-Comparison
6 -X- _ I-Comparison
days. -X- _ I-Comparison
Paraffin-stimulated -X- _ O
whole -X- _ O
saliva -X- _ O
was -X- _ O
collected -X- _ O
on -X- _ O
day -X- _ O
1 -X- _ O
( -X- _ O
before -X- _ O
the -X- _ O
onset -X- _ O
of -X- _ O
medication -X- _ O
) -X- _ O
, -X- _ O
day -X- _ O
7 -X- _ O
( -X- _ O
posttreatment -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
day -X- _ O
21 -X- _ O
( -X- _ O
follow-up -X- _ O
) -X- _ O
. -X- _ O
Results. -X- _ O
Salivary -X- _ B-Outcome
flow -X- _ I-Outcome
rate -X- _ I-Outcome
, -X- _ I-Outcome
innate -X- _ I-Outcome
host -X- _ I-Outcome
defense -X- _ I-Outcome
factors -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
total -X- _ I-Outcome
protein -X- _ I-Outcome
content -X- _ I-Outcome
were -X- _ I-Outcome
not -X- _ I-Outcome
affected -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
common -X- _ I-Outcome
cold. -X- _ I-Outcome
IgA -X- _ I-Outcome
increased -X- _ I-Outcome
between -X- _ I-Outcome
day -X- _ I-Outcome
7 -X- _ I-Outcome
and -X- _ I-Outcome
day -X- _ I-Outcome
21 -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
≤ -X- _ I-Outcome
.01 -X- _ I-Outcome
; -X- _ I-Outcome
Student -X- _ I-Outcome
2-tailed -X- _ I-Outcome
t -X- _ I-Outcome
test -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
relative -X- _ I-Outcome
proportions -X- _ I-Outcome
of -X- _ I-Outcome
salivary -X- _ I-Outcome
peroxidase -X- _ I-Outcome
and -X- _ I-Outcome
IgA -X- _ I-Outcome
increased -X- _ I-Outcome
on -X- _ I-Outcome
day -X- _ I-Outcome
7 -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.01 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
day -X- _ I-Outcome
21 -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.05 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
In -X- _ I-Outcome
patients -X- _ I-Outcome
receiving -X- _ I-Outcome
fluticasone -X- _ I-Outcome
, -X- _ I-Outcome
saliva -X- _ I-Outcome
flow -X- _ I-Outcome
rate -X- _ I-Outcome
was -X- _ I-Outcome
lower -X- _ I-Outcome
on -X- _ I-Outcome
day -X- _ I-Outcome
21 -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
≤ -X- _ I-Outcome
.05 -X- _ I-Outcome
) -X- _ I-Outcome
than -X- _ I-Outcome
on -X- _ I-Outcome
days -X- _ I-Outcome
1 -X- _ I-Outcome
and -X- _ I-Outcome
7. -X- _ I-Outcome
The -X- _ I-Outcome
innate -X- _ I-Outcome
salivary -X- _ I-Outcome
defense -X- _ I-Outcome
factors -X- _ I-Outcome
were -X- _ I-Outcome
not -X- _ I-Outcome
affected -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
IgA -X- _ I-Outcome
increased -X- _ I-Outcome
both -X- _ I-Outcome
on -X- _ I-Outcome
day -X- _ I-Outcome
7 -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
≤ -X- _ I-Outcome
.001 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
on -X- _ I-Outcome
day -X- _ I-Outcome
21 -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
≤ -X- _ I-Outcome
.001 -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
comparison -X- _ I-Outcome
with -X- _ I-Outcome
day -X- _ I-Outcome
1. -X- _ I-Outcome
Conclusions. -X- _ O
Of -X- _ O
the -X- _ O
oral -X- _ O
mucosal -X- _ O
defense -X- _ O
factors -X- _ O
, -X- _ O
only -X- _ O
IgA -X- _ O
is -X- _ O
activated -X- _ O
during -X- _ O
the -X- _ O
common -X- _ O
cold. -X- _ O
Intranasally -X- _ O
administrated -X- _ O
fluticasone -X- _ O
propionate -X- _ O
does -X- _ O
not -X- _ O
have -X- _ O
a -X- _ O
suppressive -X- _ O
effect -X- _ O
on -X- _ O
salivary -X- _ O
antimicrobial -X- _ O
capacity. -X- _ O
( -X- _ O
Oral -X- _ O
Surg -X- _ O
Oral -X- _ O
Med -X- _ O
Oral -X- _ O
Pathol -X- _ O
Oral -X- _ O
Radiol -X- _ O
Endod -X- _ O
1999 -X- _ O
; -X- _ O
87:695-9 -X- _ O
) -X- _ O

